PT  - JOURNAL ARTICLE
AU  - Tunesi, Simone
AU  - Dû, Damien Le
AU  - Gualano, Gina
AU  - Millet, Joan-Pau
AU  - Skrahin, Aliaksandr
AU  - Bothamley, Graham
AU  - Casas, Xavier
AU  - Goletti, Delia
AU  - Lange, Christoph
AU  - Musso, Maria
AU  - Palmieri, Fabrizio
AU  - Pourcher, Valérie
AU  - Rioux, Christophe
AU  - Skrahina, Alena
AU  - Veziris, Nicolas
AU  - Viatushka, Dzmitry
AU  - Jachym-Fréchet, Mathilde
AU  - Guglielmetti, Lorenzo
AU - for the TBnet
AU - the ESGMYC
AU - the French MDR-TB Group
TI  - Co-administration of treatment for rifampicin-resistant tuberculosis and chronic hepatitis C virus infection: a TBnet and ESGMYC study
AID  - 10.1101/2021.10.16.21265043
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.16.21265043
4099  - http://medrxiv.org/content/early/2021/10/18/2021.10.16.21265043.short
4100  - http://medrxiv.org/content/early/2021/10/18/2021.10.16.21265043.full
AB  - Concomitant treatment for chronic hepatitis C virus infection and multidrug-resistant tuberculosis is safe and effective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was provided by the Institutional Review Board of the coordinating centre (Bligny Hospital, Briis-sous-Forges, France) and by other participating centres.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors